AnaptysBio, Inc.
ANAB
$26.58
$0.240.91%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 32.27% | 156.61% | 184.54% | 41.65% | 573.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.27% | 156.61% | 184.54% | 41.65% | 573.39% |
| Cost of Revenue | 43.43% | 39.95% | 57.95% | 55.25% | -12.71% |
| Gross Profit | -48.01% | -32.68% | -50.11% | -55.87% | 35.70% |
| SG&A Expenses | 9.24% | 14.78% | 30.71% | 54.48% | 74.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.62% | 32.74% | 50.28% | 55.07% | 1.91% |
| Operating Income | -33.97% | -27.33% | -44.40% | -55.53% | 16.64% |
| Income Before Tax | -59.97% | -11.36% | -22.40% | -22.07% | 18.90% |
| Income Tax Expenses | -116.67% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.81% | -11.36% | -22.40% | -22.07% | 18.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.81% | -11.36% | -22.40% | -22.07% | 18.82% |
| EBIT | -33.97% | -27.33% | -44.40% | -55.53% | 16.64% |
| EBITDA | -34.29% | -27.51% | -44.67% | -55.83% | 16.79% |
| EPS Basic | -71.00% | -18.67% | -29.64% | -21.02% | 21.43% |
| Normalized Basic EPS | -41.41% | -18.67% | -29.64% | -32.73% | 21.50% |
| EPS Diluted | -70.17% | -19.06% | -29.96% | -21.02% | 21.03% |
| Normalized Diluted EPS | -41.41% | -18.67% | -29.64% | -32.73% | 21.50% |
| Average Basic Shares Outstanding | -6.54% | -6.16% | -5.58% | 0.87% | 3.31% |
| Average Diluted Shares Outstanding | -6.54% | -6.16% | -5.58% | 0.87% | 3.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
